Structure Therapeutics, Inc. (GPCR)
16.88
-0.24
(-1.40%)
USD |
NASDAQ |
Nov 20, 10:21
Structure Therapeutics Free Cash Flow : -278.01M for Sept. 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| September 30, 2026 | -278.01M |
| June 30, 2026 | -225.05M |
| March 31, 2026 | -159.70M |
| December 31, 2025 | -226.41M |
| September 30, 2025 | -196.67M |
| June 30, 2025 | -164.60M |
| Date | Value |
|---|---|
| March 31, 2025 | -136.42M |
| December 31, 2024 | -117.99M |
| September 30, 2024 | -104.60M |
| June 30, 2024 | -105.58M |
| March 31, 2024 | -95.59M |
| December 31, 2023 | -81.58M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Eli Lilly & Co. | 11.69B |
| Novo Nordisk A/S | 6.978B |
| Merck & Co., Inc. | 14.75B |
| Prestige Consumer Healthcare, Inc. | 214.22M |
| Pfizer Inc. | 11.79B |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -101.92M |
| Cash from Investing (Quarterly) | 50.45M |
| Cash from Financing (Quarterly) | 0.7356M |
| Free Cash Flow Per Share (Quarterly) | -1.449 |
| Free Cash Flow to Equity (Quarterly) | -106.17M |
| Free Cash Flow to Firm (Quarterly) | -105.57M |
| Free Cash Flow Yield | -23.08% |